Novoprotein(688137)

Search documents
近岸蛋白(688137) - 2022 Q4 - 年度财报
2023-04-28 16:00
Financial Performance - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[16]. - The company's operating revenue for 2022 was ¥264,553,718, a decrease of 22.62% compared to ¥341,895,855.16 in 2021[28]. - The net profit attributable to shareholders decreased by 39.32% to ¥90,416,734.36 from ¥149,005,616.48 in the previous year[30]. - The net profit after deducting non-recurring gains and losses fell by 47.88% to ¥77,596,888.20 compared to ¥148,869,293.75 in 2021[30]. - The company achieved operating revenue of RMB 87,842,857.29, a year-on-year increase of 12% compared to RMB 78,494,682.3 in 2021[33]. - The net profit attributable to shareholders was RMB 39,897,088.36, representing a 27% increase from RMB 31,405,202.5 in the previous year[33]. - The company reported cash flow from operating activities of RMB 7,020,963.80, an increase from RMB 4,114,032.74 in 2021[33]. - The company reported a significant increase in cash and cash equivalents, with a net increase of 739,935,737.21 RMB, up 512.77% from the previous year[162]. - The company achieved operating revenue of ¥264,553,718, a decrease of 22.91% compared to the previous year, with product revenue at ¥255,579,959.75[144]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% year-over-year growth[194]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% year-over-year growth[196]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2022, representing a 20% growth compared to the previous year[199]. Market Presence and Client Engagement - As of the end of the reporting period, the company has over 100 clients in the mRNA vaccine production sector, indicating a growing market presence[4]. - The company is expanding its market presence, targeting D new regions, which is expected to enhance overall market share by E%[16]. - The company is actively pursuing market expansion through the development of new diagnostic reagents and mRNA vaccine candidates[118]. - The company plans to increase marketing personnel and enhance customer engagement to expand its business in emerging markets[148]. - The company is focusing on sustainability initiatives, aiming to reduce carbon emissions by 25% over the next five years[194]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 300 million allocated for this purpose[199]. Research and Development - The R&D budget has increased by G%, focusing on advancements in gene editing and mRNA vaccine technologies[16]. - The company launched over 100 new innovative products during the reporting period, enhancing its product offerings[44]. - The company added 34 new R&D personnel, increasing its investment in research and development[44]. - The company reported a total R&D investment of approximately ¥41.1 million, representing a 20.55% increase compared to the previous year, with R&D expenses accounting for 15.54% of total revenue[115]. - The company is developing a one-stop service for innovative antibody research and mRNA synthesis, successfully serving dozens of clients[112]. - The company is actively collaborating with research institutions and universities to advance the development of mRNA vaccines in basic research[61]. - The company has developed 23 core technologies related to protein design, modification, and production, which remain unchanged during the reporting period[97]. - The company has established a comprehensive technology platform for antibody discovery and diagnostic reagents, leveraging expertise in molecular biology and protein engineering[97]. - The company is focusing on mRNA technology, aiming to provide related CRO services and expand into emerging fields like organoids and cell therapy[178]. Competitive Landscape and Risks - The company faces risks of revenue decline in its mRNA raw enzyme and diagnostic antibody businesses due to industry competition and uncertainties in client product development[4]. - The recombinant protein and related technology service market is expanding rapidly, attracting more domestic and international competitors, which may increase competitive pressure on the company[5]. - There is a risk of increased inventory levels due to market changes, which could lead to unsold products and potential write-downs[6]. - The company acknowledges the potential for intensified market competition and the need for increased R&D investment to maintain its competitive edge[5]. - The company faces risks related to the fluctuation of product sales prices, which have shown a downward trend[139]. Strategic Initiatives - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 35,087,719.50, which represents 38.8% of the net profit attributable to shareholders for 2022[8]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2022 fiscal year[8]. - The company will enhance its marketing and service capabilities to improve customer coverage and satisfaction[178]. - The company aims to increase market share by expanding its business team and enhancing digital marketing efforts[181]. - The company will consider investments and acquisitions in related upstream and downstream industries to enhance its business and industry layout[184]. Operational Efficiency - The gross margin improved to I%, reflecting better cost management and operational efficiencies[16]. - The company has implemented a comprehensive quality management system that includes periodic audits of raw material suppliers and stringent testing for residual impurities[128]. - The company has successfully implemented a quality management system compliant with GMP standards, ensuring product safety and stability through rigorous quality control measures[126]. - The company achieved significant advancements in mRNA vaccine drug development, including the launch of GMP-grade nucleotides and modified nucleotides, contributing to clinical projects and regulatory approvals for multiple partners[109]. Shareholder Engagement - The company held its first extraordinary general meeting of 2022 on March 4, 2022, where all proposals were approved by shareholders[187]. - The second extraordinary general meeting took place on November 28, 2022, with all proposals also receiving shareholder approval[188]. - The total pre-tax remuneration for key management personnel during the reporting period amounted to CNY 577.42 million[191]. - The chairman and general manager, Zhu Huaxing, maintained a shareholding of 15,343,004 shares throughout the year[190]. - The company’s board of directors and senior management have remained stable with no significant changes in shareholdings[190].
近岸蛋白(688137) - 2022 Q4 - 年度财报
2023-04-26 16:00
Financial Performance - Operating revenue for 2022 was ¥264,553,718, a decrease of 22.62% compared to ¥341,895,855 in 2021[21]. - Net profit attributable to shareholders was ¥90,416,734, down 39.32% from ¥149,005,616 in the previous year[21]. - Basic earnings per share decreased by 57% to ¥1.59 from ¥3.73 in 2021[23]. - The net cash flow from operating activities dropped significantly by 95.24% to ¥3,376,641 from ¥70,966,537 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥77,596,888, a decrease of 47.88% from ¥148,869,293 in 2021[21]. - The company reported a significant increase in net assets attributable to shareholders, rising by 511.33% to ¥2,199,386,246.43 from ¥359,772,635.07 in 2021[22]. - The quarterly operating revenue for Q4 2022 was ¥51,923,824.83, showing a decline compared to previous quarters[25]. - In 2022, the company achieved operating revenue of RMB 264.55 million, a year-on-year decrease of 22.62%, and a net profit attributable to the parent company of RMB 90.42 million, with a decrease of 47.88% in net profit after deducting non-recurring gains and losses[34]. - The company reported a total revenue of 1.2 billion in 2022, representing a year-over-year growth of 15%[165]. - The company provided guidance for 2023, expecting revenue to grow by 10% to 1.32 billion[165]. Dividend Policy - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 35,087,719.50, which accounts for 38.8% of the net profit attributable to shareholders for 2022[6]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2022 fiscal year[6]. - The company has a cash dividend policy that emphasizes a stable and reasonable return to investors, with a minimum cash distribution of 30% of the average distributable profit over the last three years[186]. - In mature stages without major capital expenditure, the cash dividend proportion should be at least 80% of the profit distribution[186]. - The company has not proposed any cash profit distribution plan during the reporting period despite having positive distributable profits[190]. Market and Competition - The company faces risks of revenue decline in its mRNA raw enzyme and diagnostic antibody businesses due to industry cycle impacts and uncertainties in the mRNA vaccine sector[4]. - The recombinant protein and related technology service market is expanding, but increased competition from new entrants may pressure the company's market position[5]. - The company anticipates further market competition as more players enter the recombinant protein industry, which may impact market share and pricing strategies[125]. - The company is focused on advancing mRNA technology platforms, including new delivery systems and adjuvants, to enhance vaccine efficacy[50]. - The company aims to expand its market presence through strategic collaborations and technological advancements in mRNA production[51]. Research and Development - Research and development expenses accounted for 15.54% of operating revenue, an increase of 56 basis points from 9.97% in 2021[23]. - The company established a professional R&D team of 235 members, contributing to continuous product and technology innovation[39]. - The company has developed 23 core technologies related to protein design, modification, and production, showcasing its advanced capabilities in the field[85]. - The company is actively enhancing its R&D investment in mRNA-related products and technologies to improve vaccine development services[149]. - The company has developed high-quality mRNA production key raw materials, including T7 RNA polymerase and mRNA Cap 2'-O-methyltransferase, which have reached international advanced levels[109]. Operational Efficiency - The company emphasizes internal control and management optimization, enhancing its operational efficiency and compliance with business processes[40]. - The production process adheres to ISO9001:2015 and ISO13485:2016 quality management systems, ensuring product quality and stability[59]. - The company has established a complete quality management system, ensuring product safety and stability through rigorous quality control measures[115]. - Operating expenses were reduced by 5% due to improved operational efficiencies[165]. - The company has implemented a comprehensive quality control system for large-scale production of recombinant proteins and antibodies[54]. Strategic Initiatives - The company successfully listed on the Sci-Tech Innovation Board on September 29, 2022, raising a net amount of RMB 1.74 billion for R&D, industrialization, and marketing network development[34]. - The company completed a strategic acquisition for 200 million, enhancing its product portfolio[165]. - The company is exploring potential acquisitions to bolster its product portfolio, with a budget of $100 million allocated for this purpose[168]. - The company has established partnerships with over 100 vaccine production clients, including Watson Bio and Livanda Bio, to ensure quality and supply of mRNA raw materials[51]. Employee and Governance - The company has a total workforce of 675 employees, a year-on-year increase of 32.47%, with 22.86% holding a master's degree or higher[39]. - The company emphasizes talent development, collaborating with renowned universities and research institutions to cultivate a skilled R&D team[116]. - The company has established a governance framework that includes a board of directors and various committees to ensure compliance and effective decision-making[155]. - The total remuneration for directors, supervisors, and senior management is determined based on internal management regulations and industry standards[173]. - The company has established specialized committees under the board, including the audit committee, nomination committee, remuneration and assessment committee, and strategic committee[176]. Risks and Challenges - The company acknowledges potential risks related to inventory management and the possibility of product obsolescence due to market changes[5]. - The company faces risks related to the potential decline in sales from its non-COVID business segments if it fails to achieve scale in other areas[118]. - The company is exposed to risks from changes in tax policies that could affect its preferential tax rate of 15% for high-tech enterprises[123]. - The company reported a significant reliance on a few major customers, with over 50% of sales attributed to a single customer[139]. Environmental and Social Responsibility - The company has established environmental protection mechanisms and complies with relevant laws and regulations, including the Environmental Protection Law of the People's Republic of China[196]. - There were no administrative penalties due to environmental issues during the reporting period[195]. - The company emphasizes employee rights protection, ensuring timely payment of social insurance and promoting employee training and career development[200].
近岸蛋白(688137) - 2023 Q1 - 季度财报
2023-04-26 16:00
Financial Performance - The company's operating revenue for Q1 2023 was CNY 43,002,533.69, representing a decrease of 51.05% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was CNY 11,141,255.79, down 72.08% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 83.12% in Q1 2023[9] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.16, reflecting a decline of 78.95%[6] - The weighted average return on equity decreased by 9.97 percentage points to 0.51% in Q1 2023[6] - The company reported a significant decline in revenue primarily due to a drop in unconventional diagnostic antibody sales, but excluding this, business revenue increased by 39% year-on-year[9] - Total operating revenue for Q1 2023 was ¥43,002,533.69, a decrease of 51.0% compared to ¥87,842,857.29 in Q1 2022[18] - Net profit for Q1 2023 was ¥11,140,705.59, down 72.1% from ¥39,962,894.18 in Q1 2022[19] - The company reported a total profit of ¥9,841,111.88 for Q1 2023, down 79.3% from ¥47,556,801.85 in Q1 2022[19] - Basic earnings per share for Q1 2023 were ¥0.16, a decrease of 78.9% from ¥0.76 in Q1 2022[19] Research and Development - Research and development expenses totaled CNY 11,008,017.25, accounting for 25.60% of operating revenue, an increase of 14.58 percentage points[6] - Research and development expenses rose to ¥11,008,017.25 in Q1 2023, compared to ¥9,680,652.72 in Q1 2022, an increase of 13.7%[18] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 2,353,123,774.86, a slight increase of 0.63% from the end of the previous year[6] - As of March 31, 2023, the company's total current assets amounted to RMB 2,149,706,056.96, slightly up from RMB 2,135,154,615.28 at the end of 2022, indicating a growth of approximately 0.03%[15] - The total liabilities of the company as of March 31, 2023, were RMB 141,119,651.87, compared to RMB 138,911,832.07 at the end of 2022, showing a slight increase of approximately 1%[16] - The total assets of the company reached RMB 2,353,123,774.86, up from RMB 2,338,298,078.50, reflecting a growth of about 0.63%[16] - The company's total equity increased to RMB 2,212,004,122.99 from RMB 2,199,386,246.43, marking an increase of approximately 0.67%[16] - The company's accounts receivable decreased to RMB 104,582,842.79 from RMB 118,891,144.58, a decline of about 11.99%[14] - The inventory level rose to RMB 94,403,352.24 from RMB 77,079,735.58, indicating an increase of approximately 22.5%[14] Cash Flow and Investments - Operating cash flow for Q1 2023 increased to ¥23,744,113.03 from ¥7,020,963.80 in Q1 2022, marking a significant improvement[20] - Cash and cash equivalents at the end of Q1 2023 totaled ¥1,485,658,036.01, up from ¥175,867,713.02 at the end of Q1 2022[21] - The company's cash and cash equivalents increased significantly to RMB 1,486,231,440.33 from RMB 929,924,309.17, representing a growth of about 60%[14] - The company generated investment cash inflow of ¥1,150,562,943.82 in Q1 2023, with a net cash flow from investment activities of ¥537,664,522.63[21] - The company reported a significant increase in cash reserves, which may support future investments and operational expansions[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,865[11] Government Subsidies - The company received government subsidies amounting to CNY 581,100.00, which are closely related to its normal business operations[7] Other Information - The company's short-term borrowings and other liabilities were not detailed in the provided data, indicating a focus on maintaining liquidity and managing debt levels[16] - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - The company incurred a foreign exchange loss of ¥51,237.11 in Q1 2023, compared to a loss of ¥158,968.72 in Q1 2022[21]
近岸蛋白(688137) - 2022 Q3 - 季度财报
2022-10-27 16:00
Financial Performance - The company's operating revenue for Q3 2022 was ¥46,292,353.53, a decrease of 68.40% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥18,802,760.66, down 74.78% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,438,667.48, a decline of 76.61% compared to the previous year[5] - Basic earnings per share for Q3 2022 were ¥0.3573, down 77.20% from the same period last year[6] - Total operating revenue for the first three quarters of 2022 was CNY 212,629,893.17, a decrease of 23.4% compared to CNY 277,583,731.81 in the same period of 2021[23] - Net profit for the first three quarters of 2022 was CNY 90,105,051.52, a decline of 29.5% from CNY 127,816,354.33 in the same period of 2021[24] - Basic and diluted earnings per share for the first three quarters of 2022 were CNY 1.71, compared to CNY 3.52 in the same period of 2021[25] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period was ¥9,898,324.44, reflecting a decrease of 79.42%[6] - The company experienced a net cash outflow from operating activities, indicating potential liquidity challenges moving forward[27] - Net cash flow from operating activities was $9,898,324.44, a decrease of 79.5% compared to $48,091,554.69 in the previous year[28] - Total cash inflow from financing activities reached $1,764,560,776.77, significantly up from $117,670,174.00 in the same quarter last year[29] - Cash and cash equivalents at the end of the period totaled $1,698,855,837.31, compared to $188,009,100.59 at the end of the previous year[29] - The net increase in cash and cash equivalents for the quarter was $1,509,464,027.27, compared to $119,369,848.87 in the same quarter last year[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,363,348,720.91, an increase of 360.60% compared to the end of the previous year[6] - Total liabilities as of the end of Q3 2022 were CNY 166,373,101.81, an increase from CNY 153,330,102.24 at the end of Q3 2021[20] - The company reported a decrease in accounts payable from ¥44,023,181.57 to ¥23,638,448.18, a reduction of approximately 46.3%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,882[14] - The largest shareholder, Shanghai Xinbainuo Biotechnology Co., Ltd., holds 30,355,000 shares, accounting for 43.26% of total shares[14] - Total equity attributable to shareholders of the parent company was CNY 2,196,975,619.10, significantly up from CNY 359,772,635.07 in the previous year[20] Research and Development - Research and development expenses totaled ¥10,474,557.34, representing 22.63% of operating revenue, an increase from 14.23% in the previous year[6] - The company reported a decrease in research and development expenses to CNY 28,484,447.30 from CNY 24,221,352.19 year-over-year[23] - The company has no new product or technology developments mentioned in the report[16] Market and Sales - The company experienced a significant decline in sales to Watson Bio, which impacted overall revenue and profit margins[11] - Cash received from sales of goods and services in the first three quarters of 2022 was CNY 197,109,482.47, a decrease from CNY 212,553,150.08 in the same period of 2021[27] Investment Activities - Cash outflow from investment activities was $262,449,345.66, compared to $202,609,530.23 in the previous year, indicating an increase of 29.5%[28] - The company did not recover any cash from investments during the quarter, compared to $177,000,000.00 in the same quarter last year[28] - The company reported cash inflow from investment activities of $9,900.00, a significant decrease from $177,995,853.12 in the previous year[28] Other Financial Metrics - The weighted average return on net assets decreased by 35.40 percentage points to 4.23%[6] - Accounts receivable increased to ¥118,583,615.61 from ¥96,578,245.44 year-over-year, reflecting a growth of approximately 22.8%[18] - Inventory levels rose to ¥77,286,267.89, compared to ¥37,190,793.04 in the previous year, indicating a growth of about 107.5%[18] - Non-current assets total ¥199,434,079.17, an increase from ¥180,879,944.65 year-over-year[19] - Deferred income tax liabilities decreased to CNY 2,754,053.35 from CNY 3,207,786.27 year-over-year[20] - The company paid $82,686,173.84 in employee compensation, an increase from $49,905,981.37 in the previous year[28] - Total cash outflow from financing activities was $5,198,826.28, down from $21,525,576.81 in the previous year, reflecting a decrease of 75.8%[29]